VivoSeq
Musculoskeletal

Tendinitis

7

Pipeline Programs

3

Active Trials

6

Companies Involved

Tendinitis is an early-stage landscape with 7 programs across 6 companies. The most active players are Eli Lilly, Taiwan Bio Therapeutics Inc., Alnylam Pharmaceuticals. 4 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

7

clinical trials

Completed3 · 43%
Not yet recruiting1 · 14%
Unknown status1 · 14%
Active, not recruiting1 · 14%
Recruiting1 · 14%

Trial Activity

7 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)